Pharmacists at the Frontline of HIV Prevention

Target Audience

The educational design of this activity addresses the needs of clinical and community pharmacists involved in the care of patients who are eligible for preexposure prophylaxis (PrEP).

Program Overview

Despite significant progress in HIV prevention efforts, new diagnoses continue to outpace national targets for ending the HIV epidemic. Pharmacists are essential partners in this effort and need to remain current on the latest guidelines and best practices for HIV preexposure and postexposure prophylaxis (PrEP and PEP).

This comprehensive, downloadable monograph is designed to meet the evolving needs of pharmacists as their scope of practice expands across the United States. This continuing education activity equips pharmacists with the clinical knowledge and practical tools necessary to initiate and monitor PrEP and PEP within the pharmacy setting. It also provides detailed instruction on integrating the latest clinical practice guidelines and recommendations into daily practice, including how to prescribe and monitor newer long-acting injectable (LAI) PrEP.

Accredited for 2.0 contact hours (0.20 CEUs) by the Accreditation Council for Pharmacy Education (ACPE), this monograph covers all key content areas required for pharmacists seeking to become PrEP and PEP providers and to meet most state board of pharmacy training standards, including:

• HIV epidemiology and disease burden
• Pharmacology, safety, and efficacy of PrEP and PEP medications (including oral tenofovir disoproxil fumarate/emtricitabine [TDF/FTC], oral tenofovir alafenamide [TAF]/FTC, cabotegravir [CAB] LAI, and lenacapavir [LEN] LAI
• Assessment of sexual health and HIV risk
• Patient-centered counseling and education
• Screening for HIV and sexually transmitted infections (STIs) and laboratory testing for PrEP/PEP eligibility
• Recent clinical practice guidelines and recommendations for PrEP provision
• Updated clinical practice guidelines for nonoccupational PEP (nPEP) prescribing and management
• Practical strategies for in-pharmacy implementation of oral and LAI PrEP
• Principles of trauma-informed care

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the professional parameters and current needs for pharmacy-based direct delivery of PEP and PrEP services
• Evaluate a patient’s potential risk of acquiring HIV in a nonthreatening, unbiased manner
• Determine patients’ PEP/PrEP clinical eligibility based on the latest clinical guidelines and patient characteristics and preferences
• Implement PEP/PrEP management services, including appropriate drug regimen selection, initiation, and ongoing monitoring
• Classify infrastructure needs for in-pharmacy implementation of PEP/PrEP prescribing, including for oral and LAI options

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-25-028-H02-P)

This is an application-based activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation. Pharmacists must check the CPE Monitor for credits within 60 days of the activity. Credit for pharmacists cannot be issued after 60 days.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Josh Havens, PharmD: Consulting Fees: Merck, ViiV Healthcare; Contracted Research: Gilead Sciences, Inc.                

Arsalan “RC” Shah, PharmD, MBA: Consulting Fees: AbbVie, Gilead Sciences, Inc.

The planners and managers at Global and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirement